NUWELLIS INC (NUWE)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
$4.66-11.57%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
QuarterlyIQ Insights · NUWE
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -87.8% |
| Our one-year growth estimate | diamond | 18.2% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 106.0 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 43 industry peers
NUWE — capital allocation — Material Modification to Rights of Security Holders
Dated 2026-10-23
Material Modification to Rights of Security Holders. To the extent required by
Why it matters: A filing would move the proposed expansion for smaller children to the next review step. The current label starts at 20 kg.
Supportive ifNuwellis files with the FDA by December 31, 2026, seeking use in patients weighing 5 kg or more.
Worry ifNo filing is announced by December 31, 2026, or the FDA does not accept the proposed label change.
Why it matters: More consoles can add to the base that drives circuit sales. Management named recurring revenue and use as key goals.
Supportive ifThe next results show more than nine consoles sold in a quarter and higher circuit revenue year over year.
Worry ifConsole sales are nine or fewer and circuit revenue falls year over year.
Why it matters: Margin rose to 76% in Q2 after reaching 70.1% in Q1. A high margin would show those gains held.
Supportive ifQ3 gross margin is 70% or higher.
Worry ifQ3 gross margin falls below 56%, the Q2 margin from a year earlier.
Why it matters: Q2 sales rose 14% year over year. Growth above that level would show the business kept its pace.
Supportive ifIn the November 11 results, Q3 net sales are above the prior-year quarter by more than 14%.
Worry ifQ3 net sales are flat or down from the prior-year quarter.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$452 on $10,000 · ±4.5% | How much price usually moves either way. |
| Bad day | $1,548 loss on $10,000 · 15.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,978 loss on $10,000 · 99.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The company reported cash runway through Q2 2027 after raising funds. A new raise sooner could point to added funding pressure.
Worry ifNuwellis reports another stock or debt raise before June 30, 2027, to fund operations.
Less concerning ifNuwellis reports enough cash to fund operations through Q2 2027 and no new financing before then.